ACT Brief: Process Architecture Over Autonomous AI, Real-Time RWE Integration, and Building RWE Infrastructure

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part three of his video interview, Abraham Gutman shared key takeaways from a presentation he gave at SCOPE X, including a pointed caution against the idea that agentic AI can run clinical trials autonomously. Gutman emphasized that process architecture is the real entry point for AI to deliver on its promise, not autonomous decision-making.
• In a new contributed article, Christopher Boone of Oracle examined how real-world evidence is shifting from a post-market footnote to concurrent validation running alongside trial data. Organizations furthest along have built unified data environments integrating EHRs, claims, and patient-reported outcomes as complementary inputs into a single evidentiary framework, enabling early signal detection rather than late-stage course corrections.
• In a new FAQ article, as the FDA formally recognizes RWE as eligible confirmatory evidence, sponsors face growing imperative to build data infrastructure and analytical capabilities for effective RWE use across the development lifecycle. The concurrent validation model fundamentally changes the nature of regulatory conversations by stress-testing evidence from multiple directions before approval.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.